52 results about "Ginsenoside Rc" patented technology

Personal care composition comprising from about 0.05% to about 5% of at least one aquaporin-stimulating compound selected from the group consisting of xanthine, caffeine; 2-amino-6-methyl-mercaptopurine; 1-methyl xanthine; 2-aminopurine; theophylline; theobromine; adenine; adenosine; kinetin; p-chlorophenoxyacetic acid; 2,4-dichlorophenoxyacetic acid; indole-3-butyric acid; indole-3-acetic acid methyl ester; beta-naphthoxyacetic acid; 2,3,5-triiodobenzoic acid; adenine hemisulfate; n-benzyl-9-(2-tetrahydropyranyl)adenine; 1,3-diphenylurea; 1-phenyl-3-(1,2,3-thiadiazol-5-yl)urea; zeatin; indole-3-acetic acid; 6-benzylaminopurine; alpha-napthaleneacetic acid; 6-2-furoylaminopurine; green tea extract; white tea extract; menthol; tea tree oil; ginsenoside-RB1; ginsenoside-RB3; ginsenoside-RC; ginsenoside-RD; ginsenoside-RE; ginsenoside-RG1; ginseng root extract; ginseng flower extract; pomegranate extract, extracts from Ajuga turkestanica; extracts from viola tricolor and combinations thereof; an additional ingredient selected from the group consisting of niacinamide, glycerin and mixtures thereof, and a dermatologically-acceptable carrier.

The invention provides a radix notoginseng extract which contains 5-10% of notoginsenoside R1, 25-36% of ginsenoside Rg1, 2.5-5% of ginsenoside Re, 30-39% of ginsenoside Rb1, 5-10% of ginsenoside Rd and at least 2% of ginsenoside Rf, ginsenoside Rh1, ginsenoside Rc, ginsenoside Rb2 and ginsenoside Rg3, wherein the ginsenoside R1, the ginsenoside Rg1, the ginsenoside Re, the ginsenoside Rb1 and the ginsenoside Rd account for 75-95% of the total weight. The invention also provides a preparation method of the radix notoginseng extract. The radix notoginseng extract prepared by the method has little impurities, the purity of the component of total saponin is higher, and especially, the components of the ginsenoside Rf, the ginsenoside Rh1, the ginsenoside Rc, the ginsenoside Rb2, the ginsenoside Rg3 and the like with very low content are purified. The medicinal preparation prepared by the radix notoginseng extract has better curative effect and higher safety.

The present invention relates to Chinese medicine and its extracting and processing technology, and is especially the effective part extracted from American ginseng leaf and ginseng leaf and its preparation process. The extracted effective part contains six kinds of ginsenoside substances, including ginsenoside Re, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc and ginsenoside Rd. Its preparation process includes water extracting American ginseng leaf and ginseng leaf in the weight ratio of 1 to 0.3, macroporous resin adsorption of the water extract liquid, water eluting to eliminate impurity, further eluting with two kinds of elutents, collecting the eluted liquid, and refining the total solid matter to reach purity up to 63.45 %. The extracted effective part has less side effects, and may be used widely in compound medicine preparation and functional food and for separating ginsenoside substance.

The invention provides a medicinal composition, which comprises the following components: ginsenoside Rb1, ginsenoside Rg1, notoginsenoside R1, ginsenoside Rd, ginsenoside Re, ginsenoside Rf, ginsenoside Rc, ginsenoside Rh1, ginsenoside Rb2 and ginsenoside Rg3. The invention also provides a preparation method for the medicinal composition. The medicinal composition has definite components; compared with the total notoginsenoside in the prior art, the medicinal composition has stable quality and good controllability; and results of experiments of acute toxicity, undue toxicity, hemolysis and the like show that the medicinal composition has higher safety and wide clinical application prospect.

The invention discloses a method for extracting and separating total saponins of panax ginseng from american ginseng. The method employs a series of high-efficiency extraction, separation and purification technical measures of alcohol-backflow extracting, water precipitating, purifying by a macroporous adsorption resin, decolorizing with an ion exchange resin, etc. The obtained total saponins of panax ginseng are white powder and comprise ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rc and ginsenoside Rd, wherein the total purity of ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1 is more than 74.0%. The production process is simple and practical, has no pollution, and is suitable for large-scale production.

A process for preparing ginsenoside monomer from ginseng leaf includes such steps as preparing general ginsenoside from ginseng leaf, chromatography with alumina column to obtain several groups of ginsenosides, and chromatography by column to obtain different ginsenoside monomers.

The invention provides application of a panaxadiol saponins fraction in preparing a medicine for preventing dermatitis and scar and a health-care cosmetic. The panaxadiol saponins fraction comprises the following main constituents: ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc and ginsenoside Rd. The medicine or the cosmetic is prepared from active constituents in the single panaxadiol saponins fraction or/and other medicines together and a pharmaceutically acceptable or cosmetic acceptable carrier. The medicine or the cosmetic is prepared by utilizing raw materials: ginseng rhizome medicinal materials, American ginseng rhizome medicinal materials, ginseng stem leaf medicinal materials, American ginseng leaf medicinal materials and total extractives or total saponins of the ginseng rhizome medicinal materials, the American ginseng rhizome medicinal materials, the ginseng stem leaf medicinal materials and American ginseng leaf medicinal materials through a chromatographic separation and purification method combining macroporous resin column chromatography and octadecylsilane chemically bonded silica column chromatography. The scar can be prevented from forming while the tissue regeneration and repair are promoted by the medicine or the cosmetic. Compared with glucocorticoids, cellular immunity is integrally regulated, the drug action is stable after the medicine is suspended, and the drug action advantage is obvious. The medicine or the health-care cosmetic is highly safe. The structural formula of panaxadiol saponins is shown in the specification.

The invention provides a panax notoginseng saponin composition and a preparation method and application thereof.The composition is prepared from, by weight, 30-50% of ginsenoside Rg1, 25-40% of ginsenoside Rb1, 7-16% of notoginsenoside R1, 2.7-8% of ginsenoside Re, 0.5-7.0% of ginsenoside Rd, 0.5-2% of ginsenoside Rf, 0.3-2.0% of ginsenoside Rh2, 1-3% of ginsenoside Rc, 0.3-2.5% of ginsenoside Rb3 and 0.5-2.5% of ginsenoside Rg3, wherein ginsenoside Rg1, ginsenoside Rb1 and notoginsenoside R1 account for 70-95% of the total weight of the active components, and the sum of the contents of ginsenoside Rb1 and notoginsenoside R1 is not smaller than 8 times of the content of ginsenoside Rd.Compared with commercially available Xueshuantong injections and Xueshuantong preparations, the panax notoginseng saponin composition has a more obvious arterial and venous thrombosis resistant effect, low toxicity and high safety.

The invention provides a method for measuring the content of a Shenqi blood sugar reducing preparation. The method is used for measuring the content of 10 active ingredients in the Shenqi blood sugar reducing preparation: ginsenoside Rb1, ginsenoside Rc, ginsenoside Rd, ginsenoside Rg1, ginsenoside Re, astragaloside, deoxyschizandrin, schisandrol A, schisandrol B. In the invention, with the guidance of blood sugar reducing activity of a compound, multiple active substances in the compound are detected, and the quality level of the whole compound preparation can be reflected better; meanwhile, a Q-MS ion monitoring mode is selected for content measurement, and the mass spectrum quantification has high accuracy, specificity and sensitivity and is superior to traditional HPLC analysis method; and moreover, fingerprint is established according to the liquid phase diagrams of different batches of Shenqi blood sugar reducing preparations obtained by the method, the similarity is evaluated, the inherent quality of the Shenqi blood sugar reducing preparation product is evaluated more scientifically and comprehensively, and a basis is provided for establishing a quality standard of higher level.

The invention provides application of a panaxadiol saponins fraction in preparing a medicine for preventing epilepsia. The component comprises the following main constituents: ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc and ginsenoside Rd, and the medicine is prepared from active constituents in the single panaxadiol saponins fraction or from the active constituents in the single panaxadiol saponins fraction and other medicines. By taking one of five panaxadiol saponins: ginseng, American ginseng rhizome medicinal materials, ginseng stems and leaves, American ginseng stem and leaf medicinal materials and total extractives or total saponins of the ginseng, the American ginseng rhizome medicinal materials, the ginseng stems and leaves and American ginseng stem and leaf medicinal materials as a starting raw material independently or taking a mixture which consists of two or more than two different raw materials as the starting raw material comprehensively, the medicine is prepared by establishing the chromatographic separation and purification technology. According to the medicine prepared from the panaxadiol saponins fraction provided by the invention, an anti-epileptic effect can be greatly improved, and moreover, the toxic and side effects, especially dermatitis and intelligence toxicity, of traditional anti-epileptic medicines can be resisted, therefore, long-standing defects that the anti-epileptic medicines are not enough in curative effect and low in safety are overcome. The structural formula of the panaxadiol saponin is shown in specification.

The invention discloses a method for preparing rare ginsenoside CK through gene combination transformation and application of the rare ginsenoside CK. According to the invention, glycosidase generatedby using genes of bacillus subtilis str.168 and bifidobacterium breve 689b can be used, so that the ginsenoside Rc can be converted into the rare ginsenoside CK efficiently in vitro.

The invention relates to the fields of genetic engineering technology and biomedicine, discloses alpha-L-arabinfuranosidease and a coding gene and application thereof, and specifically provides the alpha-L-arabinfuranosidease and the coding gene thereof, a recombinant vector, an expression cassette and a transgenic cell line or a recombinant strain which contain the coding gene and application ofthe alpha-L-arabinfuranosidease in preparing ginsenoside Rd. The alpha-L-arabinfuranosidease can more efficiently catalyze the reaction of ginsenoside Rc to prepare the ginsenoside Rd, and the enzymeactivity is higher; the higher activity can be exhibited both in a wider range of pH and temperature, and the stability is strong; the alpha-L-arabinfuranosidease has higher tolerance against arabinose and glucose, and facilitates the synergistic effect with other ginsenoside hydrolases.

The invention discloses a standard ginsenoside Rb1 active ingredient, containing ginsenoside Rb1 with the content more than or equal to 90% and less than 100%, is also characterized in that the active ingredient contains ginsenoside Rc with the content more than 0% and less than or equal to 10%; or the content of impurity ginsenoside Rc is more than or equal to 0.05% and less than or equal to 6.5%; or the content of ginsenoside Rc is more than or equal to 0.1% and less than or equal to 5.0%; the content of impurity ginsenoside Rc is more than or equal to 0.1% and less than or equal to 3.0%; Pharmacological experiments show that the standard active ingredient of the application has good pharmacological effects and can be prepared into pharmaceutical preparations in Pharmacy.

The invention discloses a Panax notoginseng flower total saponin, and a preparation method and an application thereof, and belongs to the field of biological medicines. The Panax notoginseng flower total saponin contains notoginsenoside Fc, ginsenoside Rc, ginsenoside Rb2, ginsenoside Rb3 and ginsenoside Rd in any proportion, and is prepared from Panax notoginseng flowers through the processes ofultrahigh-pressure extraction, filtration, concentration, drying and the like. The preparation method is carried out at normal temperature, is simple to operate and has a high efficiency, and the obtained Panax notoginseng flower total saponin has strong hydroxyl radical and DPPH free radical scavenging capacity, and can be used for preparing antioxidant drugs.

Disclosed is a method for producing ginseng fruits and flower stalks with high content of ginsenoside. More particularly, the present invention provides a method for producing ginseng fruits and flower stalks with high contents of ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rc, ginsenoside Rd, ginsenoside Re and other ginsenoside ingredients. According to the present invention, the ginseng fruits and flower stalks have considerably increased contents of ginsenoside Re, Rd and Rb2 compared with general red ginseng roots and/or black ginseng roots. In addition, the present invention can provide ginseng fruits and flower stalks based products with high contents of, especially, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rc, ginsenoside Rd and/or ginsenoside Re by processing the fruits and flower stalks.

A ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases comprises the components by weight percent: 28-32% of ginsenoside Rb1, 18-22% of ginsenoside Rg1, 14-16% of ginsenoside Rb2, 14-16% of ginsenoside Rc, 8-12% of ginsenoside Re, and 14-16% of ophiopogonin D. The advantages are that: the provided ginsenoside-ophiopogonin D composition has fixed and scientific components, controllable and stable quality, substantial drug effect and higher security, same or slightly better drug effects on (myocardial, cerebral and lung) ischemia-reperfusion injury resistance, thrombosis resistance, arteriosclerosis resistance, arrhythmia resistance and the like than shenmai injection, and more safety on acute toxicity, abnormal toxicity, hemolysis, coacervation and the like than shenmai injection. The ginsenoside-ophiopogonin D composition has the advantages of clear and fixed components, more stable and controllable quality, substantial treatment effect and higher security.

The invention belongs to a field of medicament preparation, and relates to a pharmaceutical composition for treating cardiovascular disease and a preparation method thereof, especially to the pharmaceutical composition which contains drug-efficacy component groups capable of being absorbed into blood. The drug-efficacy component groups comprise: Japanese bufotaline, ginsenoside Re, ginsenoside Ra1, 1[beta]-hydroxy bufalin, ginsenoside Rb1, resibufogenin fine alcohol, ginsenoside Rc, ginsenoside Rb2, ginsenoside, ginsenoside Rd, bufalin, cholic acid, hyodeoxy cholic acid, cinobufagin, chenodeoxycholic acid and deoxycholic acid. The medicament has clear in vivo targets, has characteristics and advantages of multi-component multi-target effects, is good in protective effects for acute myocardial ischemia, and can reduce area of myocardial infarction and content of Lactate dehydrogenase and creatine kinase in serum.

The invention discloses a Xuesaitong pharmaceutical composition and a preparation method, a preparation and application thereof. The Xuesaitong pharmaceutical composition is prepared from the following components in percentage by mass: 0.001 to 99.996% of ginsenoside Rb2, 0.001 to 99.996% of ginsenoside Rb1, 0.001 to 99.996% of ginsenoside Rg1, 0.001 to 99.996% of ginsenoside Rc, and 0.001 to 99.996% of notoginsenoside R1. The Xuesaitong pharmaceutical composition and the preparation have the advantages that the obvious treatment effect on ischemic cardiovascular and cerebrovascular diseases of myocardial infarction, cerebral apoplexy, cerebral infarction, brain hemiplegia and the like, and the retinopathy or optic nerve injury disease due to ischemic cardiovascular and cerebrovascular diseases, diabetes and the like is realized, and the application prospect is broad; compared with the prior art and the product, the treatment effect is better, the safety is higher, and the requirementof clinical medicine usage can be well met; the technology of the preparation method is simple, the conditions are mild, the operation is convenient, the quality is stable and controllable, and the preparation method is suitable for industrialized large-scale production.

The invention provides a method for determining the content of ginsenoside in a panax traditional Chinese medicine, which adopts an ultra-high performance liquid chromatography electrospray detector method to simultaneously determine the content of 15 kinds of ginsenoside in the panax traditional Chinese medicine. The 15 kinds of ginsenoside comprise notoginsenoside R1, ginsenoside Rg1, ginsenoside Re, 24 (R)-pseudoginsenoside F11, ginsenoside Rf, ginsenoside Ra2, ginsenoside Rb1, ginsenoside Rc, ginsenoside Ro, ginsenoside Rb2, ginsenoside Rb3, panax japonicus saponin IV, ginsenoside Rd, panax japonicus saponin IVa and 20 (R)-ginsenoside Rg3. By adopting the method disclosed by the invention, the contents of 15 kinds of ginsenoside in various panax traditional Chinese medicines can be simultaneously determined by reasonably selecting chromatographic conditions and detection conditions, and the method has the advantages of simplicity, convenience, accuracy, high sensitivity, strong specificity and the like, so that the method can be credibly, comprehensively and accurately used for quality control of the panax traditional Chinese medicines.

The invention discloses a pseudo-ginseng extract product, and applications thereof in preparation of cosmetics. The pseudo-ginseng extract product comprises 6 to 8% of notoginsenoside R1, 33 to 36% ofginsenoside Rg1, 3 to 5% of ginsenoside Rc, 36 to 41% of ginsenoside Rb1, and 4 to 7% of ginsenoside Rd. A preparation method of the pseudo-ginseng extract product comprises following steps: 1, freshpseudo-ginseng raw material is washed, and the washed pseudo-ginseng raw maerial and purified water are introduced into a pulverizer for crushing until a slurry mixture, which is a pseudo-ginseng slurry, is obtained; 2, the pseudo-ginseng slurry is introduced into an extraction vessel for supercritical fluid extraction so as to obtain a crude pseudo-ginseng extract product; and 3, the crude pseudo-ginseng extract product is heated with stirring, evaporation is adopted to remove a residual entrainer so as to obtain the pseudo-ginseng extract product. According to the preparation method, supercritical fluid extraction technology is adopted for pseudo-ginseng extraction, so that the using amount of organic solvents such as ethanol is reduced greatly, the purity of the pseudo-ginseng extractproduct is higher, and it is more safe for the pseudo-ginseng extract product to be used in cosmetics.

The invention provides application of ginsenoside Rc in preparation of a medicine for treating alcoholic fatty liver. Researches show that ginsenoside Rc can effectively inhibit liver injury, lipid accumulation, oxidative stress reaction and inflammatory reaction, so that acute/chronic alcoholic fatty liver is effectively treated, and a new material source is provided for the medicine for treating the alcoholic fatty liver.